Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of PG 760564 Administered Twice Daily to Healthy Male and Female Volunteers for 14 Days (27 Doses).
Phase of Trial: Phase I
Latest Information Update: 03 Nov 2011
At a glance
- Drugs PG 760564 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 03 Nov 2011 Primary endpoints identified as reported by ClinicalTrials.gov.
- 28 Nov 2008 New trial record.